Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site
Journal of Biological Chemistry · 2023
DOI: 10.1016/j.jbc.2023.102999 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023. Verfasst von Elyse M Petrunak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Prostatic Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCRR NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Abiraterone acetate is a first-line therapy for castration-resistant prostate cancer. This prodrug is deacetylated in vivo to abiraterone, which is a potent and specific inhibitor of cytochrome P450 17A1 (CYP17A1). CYP17A1 performs two sequential steps that are required for the biosynthesis of androgens that drive prostate cancer proliferation, analogous to estrogens in breast cancer. Abiraterone can be further metabolized in vivo on the steroid A ring to multiple metabolites that also inhibit CYP17A1. Despite its design as an active-site-directed substrate analog, abiraterone and its metabolites demonstrate mixed competitive/noncompetitive inhibition. To understand their binding, we solved the X-ray structures of CYP17A1 with three primary abiraterone metabolites. Despite different conformations of the steroid A ring and substituents, all three bound in the CYP17A1 active site with the steroid core packed against the I helix and the A ring C3 keto or hydroxyl oxygen forming a hydrogen bond with N202 similar to abiraterone itself. The structure of CYP17A1 with 3-keto, 5α-abiraterone was solved to 2.0 Å, the highest resolution to date for a CYP17A1 complex. This structure had additional electron density near the F/G loop, which is likely a second molecule of the inhibitor and which may explain the noncompetitive inhibition. Mutation of the adjacent Asn52 to Tyr positions its side chain in this space, maintains enzyme activity, and prevents binding of the peripheral ligand. Collectively, our findings provide further insight into abiraterone metabolite binding and CYP17A1 function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas, USA.
- Program in Biophysics, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA; Endocrinology & Metabolism Section, Medicine Service, LTC…
- Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas, USA; Program in Biophysics, University of Michigan, Ann Arbor, Michigan, USA; Department of Pharmacology, University of Michigan, Ann Arbor, Mic…
Förderung
- NCRR NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Petrunak, E. M., Bart, A. G., Peng, H. M., Auchus, R. J., & Scott, E. E. (2023). Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.102999
Vancouver
Petrunak EM, Bart AG, Peng HM, Auchus RJ, Scott EE. Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site. Journal of Biological Chemistry. 2023. doi:10.1016/j.jbc.2023.102999
BibTeX
@article{Petrunak2023,
author = {Petrunak, Elyse M and Bart, Aaron G and Peng, Hwei-Ming and Auchus, Richard J and Scott, Emily E},
title = {Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site},
journal = {Journal of Biological Chemistry},
year = {2023},
doi = {10.1016/j.jbc.2023.102999}
}
EUVIMED